A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
Journal of Clinical Psychopharmacology - United States
doi 10.1097/jcp.0000000000000702
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2017
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)